These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 35979822)

  • 1. Mineralocorticoid Receptor Antagonism by Finerenone Attenuates Established Pulmonary Hypertension in Rats.
    Tu L; Thuillet R; Perrot J; Ottaviani M; Ponsardin E; Kolkhof P; Humbert M; Viengchareun S; Lombès M; Guignabert C
    Hypertension; 2022 Oct; 79(10):2262-2273. PubMed ID: 35979822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension.
    Preston IR; Sagliani KD; Warburton RR; Hill NS; Fanburg BL; Jaffe IZ
    Am J Physiol Lung Cell Mol Physiol; 2013 May; 304(10):L678-88. PubMed ID: 23457185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension.
    Poble PB; Phan C; Quatremare T; Bordenave J; Thuillet R; Cumont A; Huertas A; Tu L; Dorfmüller P; Humbert M; Ghigna MR; Savale L; Guignabert C
    FASEB J; 2019 Mar; 33(3):3670-3679. PubMed ID: 30481487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury.
    Dutzmann J; Musmann RJ; Haertlé M; Daniel JM; Sonnenschein K; Schäfer A; Kolkhof P; Bauersachs J; Sedding DG
    PLoS One; 2017; 12(9):e0184888. PubMed ID: 28926607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mineralocorticoid receptor antagonist treatment of established pulmonary arterial hypertension improves interventricular dependence in the SU5416-hypoxia rat model.
    Lu M; Chen LY; Gairhe S; Mazer AJ; Anderson SA; Nelson JNH; Noguchi A; Siddique MAH; Dougherty EJ; Zou Y; Johnston KA; Yu ZX; Wang H; Wang S; Sun J; Solomon SB; Vanderpool RR; Solomon MA; Danner RL; Elinoff JM
    Am J Physiol Lung Cell Mol Physiol; 2022 Mar; 322(3):L315-L332. PubMed ID: 35043674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralization of CXCL12 attenuates established pulmonary hypertension in rats.
    Bordenave J; Thuillet R; Tu L; Phan C; Cumont A; Marsol C; Huertas A; Savale L; Hibert M; Galzi JL; Bonnet D; Humbert M; Frossard N; Guignabert C
    Cardiovasc Res; 2020 Mar; 116(3):686-697. PubMed ID: 31173066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology.
    Meloche J; Courchesne A; Barrier M; Carter S; Bisserier M; Paulin R; Lauzon-Joset JF; Breuils-Bonnet S; Tremblay É; Biardel S; Racine C; Courture C; Bonnet P; Majka SM; Deshaies Y; Picard F; Provencher S; Bonnet S
    J Am Heart Assoc; 2013 Jan; 2(1):e005157. PubMed ID: 23525442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Targeting of Vascular Remodeling and Right Heart Failure in Pulmonary Arterial Hypertension with a HIF-2α Inhibitor.
    Dai Z; Zhu MM; Peng Y; Machireddy N; Evans CE; Machado R; Zhang X; Zhao YY
    Am J Respir Crit Care Med; 2018 Dec; 198(11):1423-1434. PubMed ID: 29924941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of SMAD3 Promotes Vascular Remodeling in Pulmonary Arterial Hypertension via MRTF Disinhibition.
    Zabini D; Granton E; Hu Y; Miranda MZ; Weichelt U; Breuils Bonnet S; Bonnet S; Morrell NW; Connelly KA; Provencher S; Ghanim B; Klepetko W; Olschewski A; Kapus A; Kuebler WM
    Am J Respir Crit Care Med; 2018 Jan; 197(2):244-260. PubMed ID: 29095649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension.
    Chaumais MC; Djessas MRA; Thuillet R; Cumont A; Tu L; Hebert G; Gaignard P; Huertas A; Savale L; Humbert M; Guignabert C
    Cardiovasc Res; 2021 Apr; 117(5):1391-1401. PubMed ID: 32653925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.
    Lee JH; Park BK; Oh KS; Yi KY; Lim CJ; Seo HW; Lee BH
    Int Immunopharmacol; 2016 Nov; 40():196-202. PubMed ID: 27611861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling.
    Lavall D; Jacobs N; Mahfoud F; Kolkhof P; Böhm M; Laufs U
    Biochem Pharmacol; 2019 Oct; 168():173-183. PubMed ID: 31283930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NMDA-Type Glutamate Receptor Activation Promotes Vascular Remodeling and Pulmonary Arterial Hypertension.
    Dumas SJ; Bru-Mercier G; Courboulin A; Quatredeniers M; Rücker-Martin C; Antigny F; Nakhleh MK; Ranchoux B; Gouadon E; Vinhas MC; Vocelle M; Raymond N; Dorfmüller P; Fadel E; Perros F; Humbert M; Cohen-Kaminsky S
    Circulation; 2018 May; 137(22):2371-2389. PubMed ID: 29444988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension.
    Boehm M; Arnold N; Braithwaite A; Pickworth J; Lu C; Novoyatleva T; Kiely DG; Grimminger F; Ghofrani HA; Weissmann N; Seeger W; Lawrie A; Schermuly RT; Kojonazarov B
    BMC Pulm Med; 2018 Mar; 18(1):41. PubMed ID: 29499691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canagliflozin ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting pulmonary arterial smooth muscle cell proliferation.
    Tang L; Cai Q; Wang X; Li X; Li X; Chen L; Yang Y
    Clin Exp Hypertens; 2023 Dec; 45(1):2278205. PubMed ID: 37970663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease.
    Long L; Crosby A; Yang X; Southwood M; Upton PD; Kim DK; Morrell NW
    Circulation; 2009 Feb; 119(4):566-76. PubMed ID: 19153267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension.
    Nave AH; Mižíková I; Niess G; Steenbock H; Reichenberger F; Talavera ML; Veit F; Herold S; Mayer K; Vadász I; Weissmann N; Seeger W; Brinckmann J; Morty RE
    Arterioscler Thromb Vasc Biol; 2014 Jul; 34(7):1446-58. PubMed ID: 24833797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nicotinamide Phosphoribosyltransferase Promotes Pulmonary Vascular Remodeling and Is a Therapeutic Target in Pulmonary Arterial Hypertension.
    Chen J; Sysol JR; Singla S; Zhao S; Yamamura A; Valdez-Jasso D; Abbasi T; Shioura KM; Sahni S; Reddy V; Sridhar A; Gao H; Torres J; Camp SM; Tang H; Ye SQ; Comhair S; Dweik R; Hassoun P; Yuan JX; Garcia JGN; Machado RF
    Circulation; 2017 Apr; 135(16):1532-1546. PubMed ID: 28202489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratracheal Administration of Prostacyclin Analogue-incorporated Nanoparticles Ameliorates the Development of Monocrotaline and Sugen-Hypoxia-induced Pulmonary Arterial Hypertension.
    Akagi S; Nakamura K; Matsubara H; Kondo M; Miura D; Matoba T; Egashira K; Ito H
    J Cardiovasc Pharmacol; 2016 Apr; 67(4):290-8. PubMed ID: 26745002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Betaine Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats via Inhibiting Inflammatory Response.
    Yang JM; Zhou R; Zhang M; Tan HR; Yu JQ
    Molecules; 2018 May; 23(6):. PubMed ID: 29861433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.